We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.


Galapagos’ alliance strategy combines novel targets and candidate drugs discovered by Galapagos with patient expertise from Galapagos’ pharma partners. Galapagos runs these programs until candidate drug, Phase 1 or Phase 2, at which point the partner has the option to license the program.

Indication Partner Established
Global research and development collaboration Gilead 2019
Osteoarthritis Servier 2010
Inflammation and autoimmune diseases